Clinical Report: Combined Strategies for Targeting Nuclear Receptors in TB and Diabetes
Overview
This study evaluates the therapeutic potential of targeting nuclear receptors (NRs) to manage tuberculosis (TB) and type 2 diabetes mellitus (T2DM) comorbidity. Findings indicate that a combination therapy targeting Vdr, Rev-erbα, and Lxr significantly alleviates both metabolic and infectious symptoms in a comorbid mouse model.
Background
The co-occurrence of TB and T2DM poses a significant global health challenge, as diabetes increases susceptibility to TB while TB exacerbates diabetes-related complications. Understanding the interplay between these diseases is crucial for developing effective treatment strategies, particularly in regions with high prevalence rates. Nuclear receptors have emerged as promising therapeutic targets due to their roles in regulating metabolic and immune responses.
